Regression of Refractory Intraocular Large B-cell Lymphoma with Lenalidomide Monotherapy

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2011 Apr 27

PMID 21519022

Citations 14

Authors

James L Rubenstein

Patrick A Treseler

Paul J Stewart

Affiliations

Soon will be listed here.

Citing Articles

Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review.

Yan Z, Yao S, Wang Y, Liu Y, Yao Z Cancer Manag Res. 2022; 13:9489-9500.

PMID: 35002326 PMC: 8725687. DOI: 10.2147/CMAR.S341342.

Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Wu X, Zhang X, Xun R, Liu M, Sun Z, Huang J Front Immunol. 2021; 12:693200.

PMID: 34290712 PMC: 8287648. DOI: 10.3389/fimmu.2021.693200.

Insights from a Case of Vitreoretinal Lymphoma.

Damato B, Bever G, Afshar A, Rubenstein J Ocul Oncol Pathol. 2019; 5(1):13-19.

PMID: 30675472 PMC: 6341330. DOI: 10.1159/000487949.

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Rubenstein J, Geng H, Fraser E, Formaker P, Chen L, Sharma J Blood Adv. 2018; 2(13):1595-1607.

PMID: 29986852 PMC: 6039666. DOI: 10.1182/bloodadvances.2017014845.

Biology of CNS lymphoma and the potential of novel agents.

Rubenstein J Hematology Am Soc Hematol Educ Program. 2017; 2017(1):556-564.

PMID: 29222305 PMC: 6053314. DOI: 10.1182/asheducation-2017.1.556.

References

Batchelor T, Kolak G, Ciordia R, Foster C, Henson J . High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003; 9(2):711-5. View

Rubenstein J, Fridlyand J, Abrey L, Shen A, Karch J, Wang E . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007; 25(11):1350-6. DOI: 10.1200/JCO.2006.09.7311. View

Witzig T, Wiernik P, Moore T, Reeder C, Cole C, Justice G . Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009; 27(32):5404-9. DOI: 10.1200/JCO.2008.21.1169. View

Stefanovic A, Davis J, Murray T, Markoe A, Lossos I . Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. Br J Haematol. 2010; 151(1):103-6. PMC: 2950220. DOI: 10.1111/j.1365-2141.2010.08321.x. View

Berenbom A, Davila R, Lin H, Harbour J . Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2006; 21(9):1198-201. DOI: 10.1038/sj.eye.6702437. View

Frenkel S, Hendler K, Siegal T, Shalom E, Peer J . Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008; 92(3):383-8. DOI: 10.1136/bjo.2007.127928. View

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N . Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001; 19(3):742-9. DOI: 10.1200/JCO.2001.19.3.742. View

Davies F, Baz R . Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010; 24 Suppl 1:S13-9. DOI: 10.1016/S0268-960X(10)70004-7. View

Grimm S, McCannel C, Omuro A, Ferreri A, Blay J, Neuwelt E . Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008; 71(17):1355-60. PMC: 4109164. DOI: 10.1212/01.wnl.0000327672.04729.8c. View

10.

Lu L, Payvandi F, Wu L, Zhang L, Hariri R, Man H . The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2008; 77(2):78-86. DOI: 10.1016/j.mvr.2008.08.003. View

11.

Wiernik P, Lossos I, Tuscano J, Justice G, Vose J, Cole C . Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26(30):4952-7. DOI: 10.1200/JCO.2007.15.3429. View

12.

Itty S, Pulido J . Rituximab for intraocular lymphoma. Retina. 2009; 29(2):129-32. DOI: 10.1097/IAE.0b013e318192f574. View

13.

Pulido J, Bakri S, Valyi-Nagy T, Shukla D . Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina. 2007; 27(8):1071-3. DOI: 10.1097/IAE.0b013e31804ac032. View

14.

Kitzmann A, Pulido J, Mohney B, Baratz K, Grube T, Marler R . Intraocular use of rituximab. Eye (Lond). 2007; 21(12):1524-7. DOI: 10.1038/sj.eye.6702804. View

15.

Chanan-Khan A, Cheson B . Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008; 26(9):1544-52. DOI: 10.1200/JCO.2007.14.5367. View

16.

Witzig T, Vose J, Zinzani P, Reeder C, Buckstein R, Polikoff J . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011; 22(7):1622-1627. DOI: 10.1093/annonc/mdq626. View

17.

Jahnke K, Wagner T, Bechrakis N, Willerding G, Coupland S, Fischer L . Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Ann Oncol. 2005; 16(12):1974-8. DOI: 10.1093/annonc/mdi409. View